BioCardia, Inc. Expected to Earn Q3 2024 Earnings of ($1.19) Per Share (NASDAQ:BCDA)

BioCardia, Inc. (NASDAQ:BCDA) – Analysts at HC Wainwright decreased their Q3 2024 earnings per share estimates for BioCardia in a research report issued on Wednesday, August 14th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($1.19) per share for the quarter, down from their prior forecast of ($0.11). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for BioCardia’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for BioCardia’s Q4 2024 earnings at ($1.59) EPS, FY2024 earnings at ($5.06) EPS, FY2025 earnings at ($1.27) EPS, FY2026 earnings at ($1.40) EPS, FY2027 earnings at ($1.51) EPS and FY2028 earnings at ($1.14) EPS.

BioCardia Trading Up 14.5 %

BCDA stock opened at $3.32 on Friday. The business’s fifty day moving average price is $3.04 and its 200 day moving average price is $4.94. BioCardia has a 12-month low of $2.52 and a 12-month high of $23.25. The company has a market capitalization of $6.05 million, a PE ratio of -0.47 and a beta of 1.36.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.